MicroRNA Diagnostics in Subarachnoid Hemorrhage

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the profile of microRNA in cerebrospinal fluid from patients suffering subarachnoid hemorrhage with and without delayed cerebral ischemia.

Clinical Trial Description

In this study of patients suffering an aneurysmal subarachnoid hemorrhage (SAH) we would like to investigate the pathophysiological mechanisms that lead to the phenomenon delayed cerebral ischemia (DCI).

We will accomplish this through analyzing the profile of microRNA expression in the cerebrospinal fluid of SAH patients treated with extraventricular drainage.

At first we wish to compare the expression of 376 specific microRNA between 12 patients developing DCI (group 1) and 12 patients without DCI (group 2) in cerebrospinal fluid drawn on day 5 after ictus.

Secondly specific microRNAs of interest in which the expression differs between group 1 and 2 are analyzed daily to investigate the dynamic changes in expression and compared to the clinical course.

Should we find no differently expressed specific microRNAs we will compare the expression of microRNA in group 1+2 with group 3.

In addition, some of the patients as part of another clinical trial (NCT01447095

) will have established invasive neuromonitoring including microdialysis. It is our intention to develop a method for analyzing microRNA in this microdialysate.

DCI as defined by Vergouwen et al in Stroke 2010;41(10):2391-2395:

"The occurrence of focal neurological impairment (such as hemiparesis, aphasia, apraxia, hemianopia, or neglect), or a decrease of at least 2 points on the Glasgow Coma Scale (either on the total score or on one of its individual components [eye, motor on either side, verbal]). This should last for at least 1 hour, is not apparent immediately after aneurysm occlusion, and cannot be attributed to other causes by means of clinical assessment, CT or MRI scanning of the brain, and appropriate laboratory studies." ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01791257
Study type	Observational [Patient Registry]
Source	Rigshospitalet, Denmark
Contact
Status	Completed
Phase	N/A
Start date	February 2013
Completion date	January 2014

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06043167` - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Recruiting	`NCT04189471` - Recovery After Cerebral Hemorrhage
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Completed	`NCT05131295` - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.	Phase 3
Recruiting	`NCT02962349` - TRansfusion Strategies in Acute Brain INjured Patients	N/A
Completed	`NCT02872857` - Subarachnoid Hemorrhage Recovery And Galantamine	Phase 1/Phase 2
Completed	`NCT03164434` - Influence of Drainage on EVD ICP-signal
Terminated	`NCT02216513` - Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage	Phase 0
Completed	`NCT01077206` - High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage	Phase 2/Phase 3
Completed	`NCT02389634` - Identification of Novel Molecular Markers for Vasospasm
Not yet recruiting	`NCT00905931` - Lycopene Following Aneurysmal Subarachnoid Haemorrhage	Phase 2
Completed	`NCT00962546` - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage	N/A
Completed	`NCT01261091` - Early Tracheostomy in Ventilated Stroke Patients	N/A
Completed	`NCT00507104` - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed	`NCT00071565` - Familial Intracranial Aneurysm Study II	N/A
Recruiting	`NCT05113381` - The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH	N/A
Completed	`NCT04052646` - Prehospital Deaths From Spontaneous Subarachnoid Haemorrhages
Recruiting	`NCT04548596` - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting	`NCT06033378` - Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage.	N/A
Completed	`NCT04308577` - Diet Induced Ketosis for Brain Injury - A Feasibility Study	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.